<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>neglected tropical diseases &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/neglected-tropical-diseases/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 11:54:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>neglected tropical diseases &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Levamisole 3 vs 5-Day Loiasis Treatment Trial</title>
		<link>https://bioengineer.org/levamisole-3-vs-5-day-loiasis-treatment-trial/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 04 Jul 2025 21:06:39 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[3-day vs 5-day regimen]]></category>
		<category><![CDATA[immunomodulatory therapy]]></category>
		<category><![CDATA[levamisole treatment for loiasis]]></category>
		<category><![CDATA[neglected tropical diseases]]></category>
		<category><![CDATA[randomized clinical trial]]></category>
		<guid isPermaLink="false">https://bioengineer.org/levamisole-3-vs-5-day-loiasis-treatment-trial/</guid>

					<description><![CDATA[In a groundbreaking clinical trial published recently in Nature Communications, researchers have unveiled compelling evidence showcasing the safety and efficacy of levamisole regimens in treating loiasis—a parasitic infection that has long challenged medical professionals in endemic regions. This double-blind, randomized, placebo-controlled study is one of the most comprehensive assessments to date, meticulously comparing the therapeutic [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">251523</post-id>	</item>
		<item>
		<title>Decoding Resistance: How Gene Duplication Enhances Antifungal Defenses in Madurella fahalii</title>
		<link>https://bioengineer.org/decoding-resistance-how-gene-duplication-enhances-antifungal-defenses-in-madurella-fahalii/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 22 May 2025 13:28:37 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[antifungal resistance in Madurella fahalii]]></category>
		<category><![CDATA[CYP51 enzyme variants]]></category>
		<category><![CDATA[gene duplication in fungi]]></category>
		<category><![CDATA[itraconazole resistance mechanisms]]></category>
		<category><![CDATA[neglected tropical diseases]]></category>
		<guid isPermaLink="false">https://bioengineer.org/decoding-resistance-how-gene-duplication-enhances-antifungal-defenses-in-madurella-fahalii/</guid>

					<description><![CDATA[Mycetoma is a debilitating disease that predominantly affects individuals in tropical and subtropical regions, particularly within marginalized communities that lack access to comprehensive healthcare systems. This chronic infection manifests through painful swellings, skin nodules, and discharging sinuses, rendering it a significant public health concern. The most common causative agents of the fungal variant of mycetoma, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">246386</post-id>	</item>
	</channel>
</rss>
